Literature DB >> 11725819

EEG changes during long-term treatment with donepezil in Alzheimer's disease patients.

E A Kogan1, A D Korczyn, R G Virchovsky, T A Treves, M Y Neufeld.   

Abstract

In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during donepezil treatment. Comparisons of awake qEEG prior to and during treatment were performed using a 2-way analysis of variance (ANOVA) with repeated measures. In patients with mild dementia (n = 5), the qEEG analysis showed a significant reduction of the mean absolute theta activity (p = 0.05) by donepezil, particularly in frontal and temporo-parietal areas. In patients with moderate/severe dementia (n = 7), a significant decrease in the mean absolute beta 1 activity (p = 0.02), particularly in the frontal and occipital areas may be attributed to disease progression which was not counteracted by the long-term treatment. The differences in qEEG in patients with different stages of dementia under donepezil treatment may be related to different compensatory capacities due to structural and functional brain disturbances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11725819     DOI: 10.1007/s007020170006

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  12 in total

1.  Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.

Authors:  Lorena R R Gianotti; Gabriella Künig; Pascal L Faber; Dietrich Lehmann; Roberto D Pascual-Marqui; Kieko Kochi; Ursula Schreiter-Gasser
Journal:  Psychopharmacology (Berl)       Date:  2008-04-30       Impact factor: 4.530

2.  Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.

Authors:  Davide V Moretti
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

Review 3.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  New diagnostic EEG markers of the Alzheimer's disease using visibility graph.

Authors:  Mehran Ahmadlou; Hojjat Adeli; Anahita Adeli
Journal:  J Neural Transm (Vienna)       Date:  2010-08-17       Impact factor: 3.575

Review 5.  Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.

Authors:  Claudio Babiloni; Xianghong Arakaki; Hamed Azami; Karim Bennys; Katarzyna Blinowska; Laura Bonanni; Ana Bujan; Maria C Carrillo; Andrzej Cichocki; Jaisalmer de Frutos-Lucas; Claudio Del Percio; Bruno Dubois; Rebecca Edelmayer; Gary Egan; Stephane Epelbaum; Javier Escudero; Alan Evans; Francesca Farina; Keith Fargo; Alberto Fernández; Raffaele Ferri; Giovanni Frisoni; Harald Hampel; Michael G Harrington; Vesna Jelic; Jaeseung Jeong; Yang Jiang; Maciej Kaminski; Voyko Kavcic; Kerry Kilborn; Sanjeev Kumar; Alice Lam; Lew Lim; Roberta Lizio; David Lopez; Susanna Lopez; Brendan Lucey; Fernando Maestú; William J McGeown; Ian McKeith; Davide Vito Moretti; Flavio Nobili; Giuseppe Noce; John Olichney; Marco Onofrj; Ricardo Osorio; Mario Parra-Rodriguez; Tarek Rajji; Petra Ritter; Andrea Soricelli; Fabrizio Stocchi; Ioannis Tarnanas; John Paul Taylor; Stefan Teipel; Federico Tucci; Mitchell Valdes-Sosa; Pedro Valdes-Sosa; Marco Weiergräber; Gorsev Yener; Bahar Guntekin
Journal:  Alzheimers Dement       Date:  2021-04-15       Impact factor: 16.655

6.  Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics.

Authors:  Elisabeth Cw van Straaten; Philip Scheltens; Alida A Gouw; Cornelis J Stam
Journal:  Alzheimers Res Ther       Date:  2014-12-19       Impact factor: 6.982

7.  How the Post-Fracture Rehabilitation Choice Affects Brain Function in Older People?

Authors:  Noriko Mitsuboshi; Minoru Kouzuki; Shigeru Mochida; Kanehito Morimoto; Katsuya Urakami
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2019-02-07

8.  Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment.

Authors:  J A van Deursen; E F P M Vuurman; F R J Verhey; V H J M van Kranen-Mastenbroek; W J Riedel
Journal:  J Neural Transm (Vienna)       Date:  2008-07-08       Impact factor: 3.575

9.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

10.  qEEG spectral peak in Alzheimer's disease: A possible tool for treatment follow-up.

Authors:  Irina Raicher; Daniel Yasumasa Takahashi; Paulo Afonso Medeiros Kanda; Ricardo Nitrini; Renato Anghinah
Journal:  Dement Neuropsychol       Date:  2008 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.